natgillin/translations-raw huggingface dataset:
• Starting dose (for the first three to five doses): 800 mg (this equates to 12 mg for every kilogram of body weight), given every 12 hours, by injection into a vein or muscle
• Začetni odmerek (za prve tri do pet odmerkov): 800 mg (to je enakovredno 12 mg na kilogram telesne mase) na 12 ur z injekcijo v veno ali mišico.
• Week one: 20 mg/L in each dialysis bag
• prvi teden: 20 mg/l v vsako dializno vrečko,
12 mg/kg body weight intravenous or intramuscular once a day
12 mg na kg telesne mase intravensko ali intramuskularno enkrat na dan
• epileptic fits Tell your doctor or nurse straight away, if you notice any of the side effects above.
• epileptični napadi Če opazite katerega od omenjenih neželenih učinkov, takoj obvestite zdravnika ali medicinsko sestro.
After an intravenous loading dose of 12 mg/kg administered every 12 hours for 3 administrations, mean values of Cmax and Ctrough are estimated to be around 100 mg/L and 20 mg/L, respectively.
Po polnilnem odmerku 12 mg/kg intravensko na 12 ur za 3 aplikacije je ocenjena povprečna Cmax okrog 100 mg/l, ocenjena povprečna Cnajnižja pa 20 mg/l.
1 powder vial with 1 solvent ampoule 5x1 powder vials with 5x1 solvent ampoules 10x1 powder vials with 10x1 solvent ampoules 25x1 powder vials with 25x1 solvent ampoules.
1 viala s praškom z 1 ampulo z vehiklom 5 x 1 viala s praškom s 5 x 1 ampulo z vehiklom 10 x 1 viala s praškom s 10 x 1 ampulo z vehiklom 25 x 1 viala s praškom s 25 x 1 ampulo z vehiklom Na trgu morda ni vseh navedenih pakiranj.
• For most Gram-positive infections, teicoplanin trough levels of at least 10 mg/L when measured by
• Za večino grampozitivnih okužb so izmerili najnižjo koncentracijo teikoplanina vsaj 10 mg/l s tekočinsko kromatografijo visoke ločljivosti (HPLC - High Performance Liquid Chromatography)
6 mg/kg body weight intravenous or intramuscular once a day
6 mg na kg telesne mase intravensko ali intramuskularno enkrat na dan
• 10% dextrose injection
• 10 % glukoza za injekcije
Nominal teicoplanin content of vial
Nominalna količina teikoplanina v viali
5% dextrose injection
5 % glukoza za injekcije
10x1 powder vials 25x1 powder vials Not all pack sizes may be marketed.
5 x 1 viala s praškom 10 x 1 viala s praškom 25 x 1 viala s praškom Na trgu morda ni vseh navedenih pakiranj.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM [Glejte Prilogo I - Izpolni država članica]
5 powder vials
5 vial s praškom
Each vial contains 400 mg teicoplanin equivalent to not less than 400,000 IU.
Ena viala vsebuje 400 mg teikoplanina; to ustreza najmanj 400.000 i.e.
• Maintenance dose: 400 mg (this equates to 6 mg for every kilogram of body weight), given once a day, by injection into a vein or muscle
• Vzdrževalni odmerek: 400 mg (to je enakovredno 6 mg na kilogram telesne mase) enkrat na dan z injekcijo v veno ali mišico.
• Maintenance dose: 8 mg for every kilogram of body weight, given once a day, as an infusion through a drip into a vein.
• Vzdrževalni odmerek: 8 mg na kilogram telesne mase enkrat na dan kot kapalna infuzija v veno.
• you have kidney problems
• če imate težave z ledvicami,
Infusion related reactions
Z infundiranjem povezane reakcije
Each vial contains 200 mg teicoplanin equivalent to not less than 200,000 IU.
Ena viala vsebuje 200 mg teikoplanina; to ustreza najmanj 200.000 i.e.
For Targocid, powder and solvent for solution for injection/infusion or oral solution - 1 powder vial with 1 solvent ampoule - 5x1 powder vials with 5x1 solvent ampoules - 10x1 powder vials with 10x1 solvent ampoules - 25x1 powder vials with 25x1 solvent ampoules
Za zdravilo Targocid prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino - 1 viala s praškom z 1 ampulo z vehiklom - 5 x 1 viala s praškom s 5 x 1 ampulo z vehiklom - 10 x 1 viala s praškom z 10 x 1 ampulo z vehiklom - 25 x 1 viala s praškom s 25 x 1 ampulo z vehiklom
Each vial contains 100 mg teicoplanin equivalent to not less than 100,000 IU.
Ena viala vsebuje 100 mg teikoplanina; to ustreza najmanj 100.000 i.e.
The primary literature, standard volumes and treatment recommendations assume sensitivity b Collective term for a heterogeneous group of streptococcus species.
b Skupen izraz za heterogeno skupino vrst streptokokov.
You may have headaches or feel dizzy while being treated with Targocid.
Med zdravljenjem z zdravilom Targocid se lahko pojavijo glavoboli ali omotica.
• feeling or being sick (vomiting), diarrhoea
• občutek slabosti v želodcu (siljenje na bruhanje) ali bruhanje, driska
• complicated urinary tract infections,
• zapletene okužbe sečil,
teicoplanin Intramuscular, intravenous or oral uses
teikoplanin intramuskularna, intravenska ali peroralna uporaba
Volume of powder vial
Količina v viali s praškom
One single dose of 8 mg/kg body weight administered intravenously by infusion once a day.
Enkraten odmerek 8 mg/kg telesne mase v intravenski infuziji enkrat na dan.
• 5% dextrose injection
• 5 % glukoza za injekcije
Thrombocytopenia has been reported with teicoplanin.
Med uporabo teikoplanina so poročali o trombocitopeniji.
Targocid and associated names (see Annex I) 100 mg powder and solvent for solution for injection/infusion or oral solution Targocid and associated names (see Annex I) 200 mg powder and solvent for solution for injection/infusion or oral solution Targocid and associated names (see Annex I) 400 mg powder and solvent for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 100 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 200 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 400 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR 100 mg, 200 mg and 400 mg / powder and solvent for solution for injection/infusion or oral solution
ZUNANJA OVOJNINA ZA 100 mg, 200 mg in 400 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Powder and solvent for solution for injection/infusion or oral solution Powder for solution for injection/infusion or oral solution
Prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Loading dose regimen
Shema polnilnih odmerkov
Special precautions must be taken when administering teicoplanin in patients who require concomitant treatment with ototoxic and/or nephrotoxic medicinal products for which it is recommended that regular haematology, liver and kidney function tests are carried out.
Posebna previdno je treba teikoplanin uporabljati pri bolnikih, ki potrebujejo sočasno zdravljenje z ototoksičnimi in/ali nefrotoksičnimi zdravili.
For Targocid, powder for solution for injection/infusion or oral solution - 1 powder vial - 5x1 powder vials - 10x1 powder vials - 25x1 powder vials
Za zdravilo Targocid prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino - 1 viala s praškom - 5 x 1 viala s praškom - 10 x 1 viala s praškom - 25 x 1 viala s praškom
• Maintenance dose: 800 mg (this equates to 12 mg for every kilogram of body weight), given once a day hours, by injection into a vein or muscle
• Vzdrževalni odmerek: 800 mg (to je enakovredno 12 mg na kilogram telesne mase) enkrat na dan z injekcijo v veno ali mišico.
One single dose of 6-10 mg/kg body weight administered intravenously once a day.
En odmerek 6-10 mg/kg telesne mase intravensko enkrat na dan.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR 100 mg, 200 mg and 400 mg / powder for solution for injection/infusion or oral solution
ZUNANJA OVOJNINA ZA 100 mg, 200 mg in 400 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Preparation of reconstituted solution: Slowly inject the entire content of the supplied solvent into the powder vial.
Počasi injicirajte celotno količino priloženega vehikla v vialo s praškom.
Targocid and associated names (see Annex I) 100 mg powder for injection/infusion or oral solution Targocid and associated names (see Annex I) 200 mg powder for injection/infusion or oral solution Targocid and associated names (see Annex I) 400 mg powder for injection/infusion or oral solution [See Annex I - To be completed nationally]
Targocid in povezana imena (glejte Prilogo I) 100 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 200 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Targocid in povezana imena (glejte Prilogo I) 400 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino [Glejte Prilogo I - Izpolni država članica]
After reconstitution, the solution will contain 200 mg teicoplanin in 3 mL.
Po pripravi bo raztopina vsebovala 200 mg teikoplanina v 3 ml.
• you have a decrease in platelet count (thrombocytopenia)
• če imate zmanjšano število krvnih ploščic (trombocitopenija),
Respiratory, thoracic and mediastinal disorders
Bolezni dihal, prsnega koša in mediastinalne ga prostora bronhospazem
Teicoplanin is not distributed in red cells.
Teikoplanin se ne porazdeli v eritrocite.
Management
Vodenje
Powder for solution for injection/infusion or oral solution Sodium chloride
Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino natrijev klorid natrijev hidroksid (za prilagoditev pH)
One single dose of 16 mg/kg body weight, administered intravenously by infusion on the first day.
Enkraten odmerek 16 mg/kg telesne mase v intravenski infuziji prvi dan. Vzdrževalni odmerek
After reconstitution, the solution will contain 400 mg teicoplanin in 3 mL.
Po pripravi bo raztopina vsebovala 400 mg teikoplanina v 3 ml.
INSTRUCTIONS ON USE [To be completed nationally]
NAČIN IZDAJANJA ZDRAVILA [Izpolni država članica]
After reconstitution, the solutions will contain 400 mg teicoplanin in 3.0 mL.
Po pripravi bo raztopina vsebovala 400 mg teikoplanina v 3,0 ml.
Renal failure (including renal failure acute)
Bolezni sečil zvišanje kreatinina v krvi odpoved ledvic (vključno z akutno odpovedjo ledvic)
PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection/infusion or oral solution 1 powder vial and 1 solvent ampoule 5 powder vials and 5 solvent ampoules 10 powder vials and 10 solvent ampoules 25 powder vials and 25 solvent ampoules
FARMACEVTSKA OBLIKA IN VSEBINA Prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino 1 viala s praškom in 1 ampula z vehiklom
• community acquired pneumonia,
• pljučnica, dobljena v domačem okolju,
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder [See Annex I - To be completed nationally]
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet z zdravilom [Glejte Prilogo I - Izpolni država članica]
Coagulase-negative staphylococci a
Koagulaza-negativni stafilokoki a
• Starting dose (for the first three doses): 10 mg for every kilogram of body weight, given every
• Začetni odmerek (za prve tri odmerke): 400 mg (to je enakovredno 6 mg na kilogram telesne mase)
• Rash, erythema, pruritus
• izpuščaj, rdečina, srbenje
• in a Type I, colourless glass vial of useful volume of 8 mL for 100 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium red overseal.
• v viali iz brezbarvnega stekla tipa I z uporabnim volumnom 8 ml za 100 mg, zaprti z zamaškom iz brombutilne gume in plastičnim snemnim pokrovčkom rdeče aluminijske prekrivne zapore.
Targocid and associated names (see Annex I) 400 mg powder for solution for injection/infusion or oral solution [See Annex I - To be completed nationally]
Targocid in povezana imena (glejte Prilogo I) 400 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino [Glejte Prilogo I - Izpolni država članica]
How to store Targocid
Kako se daje zdravilo Targocid
Peritonitis for patients on peritoneal dialysis
Bolezni živčevja omotica, glavobol epileptični napadi
• in a Type I, colourless glass vial of useful volume of 22 mL for 400 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium green overseal.
• v viali iz brezbarvnega stekla tipa I z uporabnim volumnom 22 ml za 400 mg, zaprti z zamaškom iz brombutilne gume in plastičnim snemnim pokrovčkom zelene aluminijske prekrivne zapore.
Targocid and associated names (see Annex I) 400 mg powder and solvent for solution for injection/infusion or oral solution [See Annex I - To be completed nationally]
Targocid in povezana imena (glejte Prilogo I) 400 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino [Glejte Prilogo I - Izpolni država članica]
Type I, colourless glass vial of useful volume of 22 mL for 400 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium green overseal.
viali iz brezbarvnega stekla tipa I z uporabnim volumnom 22 ml za 400 mg, zaprti z zamaškom iz brombutilne gume in plastičnim snemnim pokrovčkom zelene aluminijske prekrivne zapore.
Type I, colourless glass vial of useful volume of 10 mL for 200 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium yellow overseal.
viali iz brezbarvnega stekla tipa I z uporabnim volumnom 10 ml za 200 mg, zaprti z zamaškom iz brombutilne gume in plastičnim snemnim pokrovčkom rumene aluminijske prekrivne zapore.
They will decide whether or not you are given this medicine while you are pregnant.
Oni bodo presodili, ali naj med nosečnostjo dobite to zdravilo ali ne. Obstaja lahko tveganje za okvaro notranjega ušesa in za težave z ledvicami.
• in a Type I, colourless glass vial of useful volume of 10 mL for 200 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium yellow overseal.
• v viali iz brezbarvnega stekla tipa I z uporabnim volumnom 10 ml za 200 mg, zaprti z zamaškom iz brombutilne gume in plastičnim snemnim pokrovčkom rumene aluminijske prekrivne zapore.
Nervous system disorders
Priprava raztopine
It is unlikely that they will not give you the medicine as prescribed.
Ni verjetno, da vam ne bi dala predpisanega zdravila.
• Ringer-lactate solution
• Ringerjeva raztopina
What Targocid looks like and contents of the pack Targocid is a powder and solvent for solution for injection/infusion or oral solution.
Izgled zdravila Targocid in vsebina pakiranja Zdravilo Targocid je prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino Prašek je gobasta, homogena masa slonokoščene barve.
Type I, colourless glass vial of useful volume of 8 mL for 100 mg closed with bromobutyl rubber stopper and plastic flip-off top aluminium red overseal.
Liofilizirano zdravilo je pakirano v: viali iz brezbarvnega stekla tipa I z uporabnim volumnom 8 ml za 100 mg, zaprti z zamaškom iz brombutilne gume in plastičnim snemnim pokrovčkom rdeče aluminijske prekrivne zapore.
Targocid and associated names (see Annex I) 400 mg powder for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 400 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Targocid and associated names (see Annex I) 200 mg powder for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 200 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Targocid and associated names (see Annex I) 100 mg powder for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 100 mg prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
For Targocid, powder and solvent for solution for injection/ infusion or oral solution What Targocid contains
Za zdravilo Targocid prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Targocid and associated names (see Annex I) 200 mg powder and solvent for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 200 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Targocid and associated names (see Annex I) 400 mg powder and solvent for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 400 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
Loading dose
Polnilni odmerek
Targocid and associated names (see Annex I) 100 mg powder and solvent for solution for injection/infusion or oral solution
Targocid in povezana imena (glejte Prilogo I) 100 mg prašek in vehikel za raztopino za injiciranje ali infundiranje ali za peroralno raztopino
There may be a potential risk of inner ear and kidney problems.
povzročijo lahko težave s sluhom, težave z ledvicami ali oboje.
Blood and the lymphatic system disorders
Bolezni krvi in limfatičnega sistema levkopenija, trombocitopenija, eozinofilija agranulocitoza, nevtropenija
MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM [Glejte Prilogo I - Izpolni država članica]
If symptoms or signs of SJS or TEN
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Shelf life of diluted medicinal product:
Rok uporabnosti redčenega zdravila:
3 (3 x 1) cartridges + 3 (3 x 1) automated minidosers (multipack)
3 (3 x 1) vložki + 3 (3 x 1) avtomatski odmerniki (skupno pakiranje)
1 cartridge + 1 automated minidoser
1 vložek + 1 avtomatski odmernik
6 (3 x 2) pre-filled pens (multipack)
6 (3x2) napolnjenih injekcijskih peresnikov (skupno pakiranje)
Content (concentration)
Številka (EU) dovoljenja za promet
Pre-filled syringe (glass)
Pot uporabe Stična ovojnina Vsebina Velikost pakiranja napolnjena injekcijska brizga (steklena)
*** International units.
*** mednarodne enote.
ATC vet code: QI07AJ.
Oznaka ATC vet: QI07AJ.
Such reactions may evolve to a more severe condition which may be life-threatening.
Take reakcije se lahko razvijejo v težja stanja, ki lahko ogrožajo življenje.
Active immunisation of dogs from 8-9 weeks of age:
Aktivna imunizacija psov, starejših od 8-9 tednov:
Suspension: pink colour with fine sediment.
Suspenzija: rožnate barve s finim sedimentom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 31/07/2014.
Datum pridobitve dovoljenja za promet: 31/07/2014.
Store and transport refrigerated (2°C-8°C).
Shranjujte in prevažajte v hladilniku (2 °C - 8 °C).
In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6-week old dogs.
Če je potrebno, lahko cepimo pse, mlajše od 8 tednov, saj je bila varnost tega cepiva dokazana pri psih, starih 6 tednov.
Pharmacotherapeutic group: Immunologicals for canidae, live and inactivated viral and inactivated bacterial vaccines.
Farmakoterapevtska skupina: Imunološka zdravila za pse (canidae), živa in inaktivirana virusna in inaktivirana bakterijska cepiva.
* Tissue culture infectious dose 50 %.
* 50% infektivnega odmerka za tkivno kulturo.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP.
Do not use in animals that are showing signs of rabies or that are suspected of being infected with rabies virus.
Ne cepite živali, ki kažejo znake stekline ali se sumi, da so okužene z virusom stekline.
However, due to the low pathogenicity of the strain, it is not necessary to keep vaccinated dogs separated from non-vaccinated dogs.
Zaradi nizke patogenosti teh sevov ločevanje cepljenih psov od necepljenih ni potrebno.
Reconstituted vaccine: pink/red, or yellowish colour with slight opalescence.
Rekonstituirano cepivo: rožnato/rdeče ali rumenkaste barve, rahlo opalescentno.
** Antibody micro agglutination-lytic reaction.
** reakcija mikroaglutinacije-lize protiteles.
≥ 2.0 IU***
≥ 2,0 i.e.***
The second dose should not be given before 12 weeks of age.
Drugega odmerka ne smete dati pred starostjo 12 tednov.
A transient swelling (up to 5 cm) may commonly be observed at the injection site following subcutaneous administration in dogs.
Prehodna oteklina (do 5 cm) se lahko pogosto pojavi na mestu injiciranjapo subkutani aplikaciji pri psih.
Shake well and administer immediately the entire content (1 ml) of the reconstituted product.
Pred uporabo dobro pretresite in takoj injicirajte živali celotno rekonstituirano vsebino (1 ml).
Systemic reactions such as lethargy, hyperthermia and general malaise may occur very rarely.
Sistemske reakcije kot so letargija, hipotermija in splošno slabo počutje se pojavljajo zelo redko.
Dose and route of administration:
Odmerjanje in pot uporabe:
Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.
Trajanje imunosti proti steklini je bilo dokazano po enkratnem cepljenju pri starosti 12 tednov.
In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).
V primeru potovanja na območja z večjim tveganjem ali izven EU se lahko veterinarji odločijo za dodatna cepljenja proti steklini po 12. tednu starosti, da zagotovijo titer protiteles v višini ≥ 0,5 i.e./ml, ki na splošno velja za učinkovito zaščito in obenem izpolnjuje zahteve za potovanje živali (titer protiteles ≥ 0,5 i.e./ml).
Aseptically reconstitute the lyophilisate with the suspension.
Aseptično rekonstituirajte liofilizat s suspenzijo.
BATCH NUMBER Lot {number}
Lot{številka}
EXP {month/year} Once reconstituted, use immediately.
EXP {mesec/leto} Rekonstituirano zdravilo uporabite uporabite takoj.
Rabies virus
Virus stekline
≥ 2.0 IU
≥ 2,0 i.e.
Two doses of Versican Plus Pi/L4R 3-4 weeks apart from 8-9 weeks of age.
Dva odmerka cepiva Versican Plus Pi/L4R v razmaku 3-4 tednov od starosti 8-9 tednov naprej.
Canine parainfluenza virus Type 2
Virus pasje parainfluence tipa 2
CLINICAL PARTICULARS 4.1 Target species Dogs
KLINIČNI PODATKI 4.1 Ciljne živalske vrste
However, in field studies 10% of sero-negative dogs did not show seroconversion (> 0.1 IU/ml) 3-4 weeks after single primary vaccination against rabies.
Študije na terenu so pokazale, da pri 10 % serološko negativnih psov ne pride do serološke konverzije (> 0,1 i.e./ml) 3-4 tedne po enkratnem osnovnem cepljenju proti steklini.
MANUFACTURER'S BATCH NUMBER Lot {number}
PROIZVAJALČEVA ŠTEVILKA SERIJE
Clinical signs of immune-mediated diseases, such as haemolytic anaemia, thrombocytopenia or polyarthritis have been reported in very rare cases.
Klinični znaki imunsko pogojenih bolezni kot so hemolitična anemija, trombocitopenija, ali poliartritis so bili opaženi v zelo redkih primerih.
At least three years following the primary vaccination course for rabies.
Vsaj tri leta po osnovnem cepljenju proti stekline.
Primary vaccination scheme:
Osnovno cepljenje:
− to prevent mortality, clinical signs and infection caused by rabies virus.
− za preprečevanje smrtnosti, kliničnih znakov in okužb, ki jih povzroča virus stekline.
A single dose of Versican Plus Pi/L4R should be given every 3 years.
Enkratni odmerek Versican Plus Pi/L4R je potrebno dati vsaka 3 leta.
Re-vaccination scheme:
Ponovno cepljenje:
The live attenuated virus vaccine strain CPiV may be shed by vaccinated animals following vaccination.
Cepljene živali lahko po cepljenju izločajo žive atenuirane vakcinalne seve CPiV.
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50 Suspension (inactivated):
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50